Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

NEVIRAPINE TABLETS FOR ORAL SUSPENSION

NEVIRAPINE

Standard Dose
50MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview NEVIRAPINE TABLETS FOR ORAL SUSPENSION is listed in Drugs@FDA under application 022299 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient NEVIRAPINE Form and strength TABLET; ORAL - 50MG Sponsor AUROBINDO PHARMA LTD Submission history Latest submission status date: 2010-02-24 00:00:00.

Structured Monograph

Clinical summary

Approval overview NEVIRAPINE TABLETS FOR ORAL SUSPENSION is listed in Drugs@FDA under application 022299 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient NEVIRAPINE Form and strength TABLET; ORAL - 50MG Sponsor AUROBINDO PHARMA LTD Submission history Latest submission status date: 2010-02-24 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
NEVIRAPINE TABLETS FOR ORAL SUSPENSION (NEVIRAPINE) | Drug Monograph | MedicHelpline